Chardan Capital Weighs in on Avidity Biosciences, Inc.'s FY2023 Earnings (NASDAQ:RNA)

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Rating) – Chardan Capital dropped their FY2023 EPS estimates for Avidity Biosciences in a report released on Wednesday, May 10th. Chardan Capital analyst K. Nakae now forecasts that the biotechnology company will earn ($2.94) per share for the year, down from their prior forecast of ($2.90). Chardan Capital currently […]

Related Keywords

,Belpointe Asset Management ,Needham Company ,Daiwa Securities Group Inc ,Itau Unibanco Holding ,Nasdaq ,Wells Fargo Company ,Credit Suisse Group ,Great West Life Assurance Co ,Avidity Biosciences Inc ,Avidity Biosciences ,Get Rating ,Chardan Capital ,Avidity Bioscience ,Suisse Group ,Biosciences Stock Down ,West Life Assurance ,Asset Management ,Daiwa Securities Group ,Securities Group ,Duchenne Muscular Dystrophy ,Avidity Biosciences Daily ,Nasdaq Rna ,Rna ,Medical ,Earnings Estimates ,